Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Core Insights - Kalaris Therapeutics has appointed Matthew Gall as Chief Financial Officer to enhance its leadership team and support the company's growth as it advances its clinical studies [1][2] - The company is focused on developing treatments for retinal diseases, particularly neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) [3] Company Overview - Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to addressing major unmet medical needs in retinal diseases [3] - The company was founded by Dr. Napoleone Ferrara, known for his pioneering research in anti-VEGF therapy [3] Leadership and Experience - Matthew Gall brings extensive experience from previous roles at iTeos Therapeutics, Sarepta Therapeutics, Celgene Corporation, and Gilead Sciences, focusing on financial operations and business development [2] - His appointment is expected to bolster Kalaris' strategic direction and support its clinical development efforts [2]